Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Tumor-Agnostic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Estrogen Receptor-positive Breast Cancer 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 183Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 93Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diet, Ketogenic × Breast × Clear all
NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Completed
31 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡